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Abstract
The CDKN1B gene encodes the cyclin-dependent kinase inhibitor p27KIP1, an atypical tumor suppressor playing a key role in
cell cycle regulation, cell proliferation, and differentiation. Impaired p27KIP1 expression and/or localization are often
observed in tumor cells, further confirming its central role in regulating the cell cycle. Recently, germline mutations in
CDKN1B have been associated with the inherited multiple endocrine neoplasia syndrome type 4, an autosomal dominant
syndrome characterized by varying combinations of tumors affecting at least two endocrine organs. In this study we
identified a 4-bp deletion in a highly conserved regulatory upstream ORF (uORF) in the 59UTR of the CDKN1B gene in a
patient with a pituitary adenoma and a well-differentiated pancreatic neoplasm. This deletion causes the shift of the uORF
termination codon with the consequent lengthening of the uORF–encoded peptide and the drastic shortening of the
intercistronic space. Our data on the immunohistochemical analysis of the patient’s pancreatic lesion, functional studies
based on dual-luciferase assays, site-directed mutagenesis, and on polysome profiling show a negative influence of this
deletion on the translation reinitiation at the CDKN1B starting site, with a consequent reduction in p27KIP1 expression. Our
findings demonstrate that, in addition to the previously described mechanisms leading to reduced p27KIP1 activity, such as
degradation via the ubiquitin/proteasome pathway or non-covalent sequestration, p27KIP1 activity can also be modulated
by an uORF and mutations affecting uORF could change p27KIP1 expression. This study adds the CDKN1B gene to the short
list of genes for which mutations that either create, delete, or severely modify their regulatory uORFs have been associated
with human diseases.
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Introduction
CDKN1B encodes the cyclin-dependent kinase (CDK) inhibitor,
p27KIP1, which negatively regulates the Cdk2/cyclin E and Cdk2/
cyclin A protein complexes, thereby preventing the progression
from the G1 to the S phase of the cell cycle [1]. In G0 and early G1,
p27KIP1 expression and stability are maximal. During the G1 phase
gradual degradation of p27KIP1 is associated with an increased
activity of Cdk2/cyclin E and Cdk2/cyclin A complexes to
stimulate cell proliferation [2,3]. Several mitogenic (i.e. MAPK,
PI3K/AKT) and anti-proliferative (i.e. TGFb/SMAD) signal
transduction pathways regulate p27KIP1 expression and activity,
making it a central integration point for cell-fate decision [4]. These
pathways can regulate p27KIP1 at different levels, including trans-
cription, translation, intracellular localization or ubiquitin-mediated
proteasomal degradation [5].
p27KIP1 acts as an atypical tumor suppressor as it is rarely
mutated in human cancers, but frequently underexpressed or
mislocalized in human malignancies [4]. Although an augmented
proteolysis was initially suggested as the major cause of p27KIP1
loss in human tumors [6], recent findings propose that reduced
translation and/or transcription of CDKN1B also contributes to
p27KIP1 deficiency [7–9].
Translation of CDKN1B may involve regulatory elements within
its 59UTR, including an internal ribosome entry site (IRES) and
an upstream ORF (uORF) [10,11]. The IRES supports p27KIP1
expression when cap-dependent translation is reduced, such as
during quiescence or stress conditions [10,12]. Reduced IRES-
mediated translation, due to mutations in the pseudouridine
synthase that alters the ribosome’s ability to efficiently engage the
CDKN1B IRES element, may contribute to the increased
predisposition to cancer in X-linked congenital dyskeratosis [13].
Germline mutations in the CDKN1B gene have been recently
associated with the development of a multiple endocrine neoplasia
syndrome both in humans (MEN4, MIM 610755) and in rats
(MENX) [14]. Multiple endocrine neoplasias, including type 1
(MEN1, MIM 131100) and type 2 variants, (MEN2, MIM
171400, MIM 162300), are a group of autosomal dominant
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syndromes characterized by varying combinations of tumors
affecting at least two endocrine organs [15].
To date, seven CDKN1B germline mutations have been
identified in MEN4 patients primarily associated with MEN1-
related lesions, including parathyroid and pituitary tumors, but
the presence of other malignancies such as renal angiomyoli-
poma, papillary thyroid carcinoma and pancreatic masses has
also been reported [8,9,14,16,17]. Two further germline
mutations have been more recently associated with sporadic
hyperparathyroidism [18]. In MEN4, CDKN1B mutations
either affect p27KIP1 cellular localization, protein stability or
the binding with functional partners such as Cdk2 or Grb2
[8,17]. Reduced transcription/translation efficiency due to
mutations in elements regulating translation initiation (i.e., in
the Kozak sequence, or forming a secondary stem loop
structure within the CDKN1B 59UTR), has also been described
[8,9].
Germline CDKN1B mutations are hence rare events in
MEN1-like subjects (individuals with MEN1-related lesions,
without MEN1 inactivating mutations), being identified in less
than 3% of cases [8,16] and a clear genotype-phenotype
correlation has not been established to date.
In the present paper we analyzed the CDKN1B gene looking for
point mutations and large rearrangements in order to determine
the possible cause of multiple endocrine tumors in 25 consecutive
sporadic and familial patients with typical MEN1-related
symptoms. We identified a 4-bp deletion that modifies the
regulatory uORF in the 59UTR of the CDKN1B gene in a patient
with tumors in the pituitary gland and the endocrine pancreas.
Functional studies based on dual-luciferase assay and site-directed
mutagenesis further support the deleterious influence of this
deletion on translation reinitiation at the CDKN1B starting site,
with a consequent reduction of p27KIP1 expression both in vitro
and in vivo.
Results/Discussion
The regulatory uORF within the CDKN1B gene is mutated
in an acromegalic patient affected by a well-
differentiated pancreatic lesion
Among the 25 patients with MEN1-related symptoms, a 4-bp
deletion (c.-456_-453delCCTT, NM_004064) within the 59UTR
of CDKN1B in a 62 year old female patient with acromegaly and a
well-differentiated non-functioning pancreatic endocrine neoplasm
has been identified. This sequence variant was not detected in
either 600 chromosomes or in the dbSNP/1000 genomes
databases.
The 59UTR of the CDKN1B gene is highly structured,
containing several translational regulatory elements. An IRES
element sustains p27KIP1 translation under poor growth conditions
[10,12], while a G/C-rich hairpin domain contributes to cell-cycle
dependent regulation of CDKN1B translation [11]. Downstream
the G/C-rich domain and encompassing the c.-456_-
453delCCTT, an uORF coding for a 29 amino acid-long peptide
has been described that has been suggested to inhibit the in vitro
synthesis of p27KIP1 and to enhance its cell cycle-dependent
translation [11]. An extensive comparative analysis of DNA and
protein sequences from multiple species (Figure 1) confirmed
previous data of high evolutionary conservation among vertebrates
of the uORF [11], and support the hypothesis of a functional role
of this element [11].
In general, uORFs are small open reading frames located in the
59UTR of genes that influence translation during ribosome
scanning, thus modulating gene expression. A scanning ribosome
encountering an uORF has multiple fates: it can i) translate the
uORF; ii) scan through the sequence (leaky scanning) and
reinitiate translation further downstream at a proximal or distal
ATG; iii) induce ribosome stalling or premature dissociation at the
uORF stop codon, thus reducing downstream-cistron translation
[19] or down-regulating gene expression by promoting mRNA
decay [20].
In our case the 4-bp deletion shifts the uORF termination codon,
thus lengthening the uORF encoded peptide from 29 to 158 amino
acids and shortening the intercistronic space from 429 to 38 bp,
with a possible negative influence on translation reinitiation from
the main ATG (Figure 2). Long uORFs and short intercistronic
regions may indeed prevent the 40S ribosomal subunits from
keeping and/or re-acquiring appropriate cofactors for translation
resumption/reinitiation at the downstream ATG [21,22].
The c.-456_-453delCCTT affects p27KIP1 expression
without altering neither the steady-state level of CDKN1B
mRNA nor the promoter usage
To address the possibility that the 4-bp deletion affects
transcription and/or mRNA stability, making a decreased
translation rate due to reduced reinitiation efficiency biologically
irrelevant, or alters the promoter usage pattern preventing
transcription of the uORF-containing isoform [10], we measured
the steady state levels of CDKN1B allelic mRNAs from whole blood
by 59RACE and allele-specific qPCR. As reported in Figure 3a,
both wild type and mutated alleles were expressed in blood cells in
almost equal amounts, suggesting that the identified deletion does
not alter mRNA steady state levels, and therefore probably does
not alter either transcription or mRNA stability. An apparently
unique 59UTR of .530 bp has been identified in the c.-456_-
453delCCTT carrier and in healthy controls, supporting the
concept that the transcription pattern is preserved in the mutated
subject (Figure 3b).
Author Summary
Gene expression can be modulated at different steps on
the way from DNA to protein including control of
transcription, translation, and post-translational modifica-
tions. An abnormality in the regulation of mRNA and
protein expression is a hallmark of many human diseases,
including cancer. In some eukaryotic genes translation
can be influenced by small DNA sequences termed
upstream open reading frames (uORFs). These elements
located upstream to the gene start codon may either
negatively influence the ability of the translational
machinery to reinitiate translation of the main protein
or, much less frequently, stimulate protein translation by
enabling the ribosomes to bypass cis-acting inhibitory
elements. CDKN1B, which encodes the cell cycle inhibitor
p27KIP1, includes an uORF in its 59UTR sequence. p27KIP1
expression is often reduced in cancer, and germline
mutations have been identified in CDKN1B in patients
affected with a syndrome (MEN4) characterized by
varying combinations of tumors in endocrine glands.
Here we show that a small deletion in the uORF upstream
to CDKN1B reduces translation reinitiation efficiency,
leading to underexpression of p27KIP1 and coinciding
with tumorigenesis. This study describes a novel mech-
anism by which p27KIP1 could be underexpressed in
human tumors. In addition, our data provide a new
insight to the unique pathogenic potential of uORFs in
human diseases.
An uORF Mutation in the CDKN1B Gene Causes MEN4
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The pancreatic tumor of the mutated patient was then analyzed
by immunohistochemistry for p27KIP1 expression and for the
proliferation antigen Ki-67, and compared with similar tumors
from CDKN1B-mutation negative subjects. Parallel differences in
expression level and localization were found. We observed weak
cytoplasmic staining in tumor cells and very strong nuclear
staining in the interspersed normal endothelial cells in the MEN4
patient (Ki67,1%), while in contrast p27KIP1 nuclear staining was
found in a high proportion of sporadic well-differentiated
pancreatic tumors examined (Figure 4). The reduction in nuclear
p27KIP1 and/or its cytoplasmic mislocalization has been reported
in different cancers including breast, colon and prostate [4]. Loss
of p27KIP1 may occur through different mechanisms, including
augmented proteasome-mediated proteolysis and impaired trans-
lation [23]. On the other hand, the cytoplasmic mislocalization
may be associated with imbalanced p27KIP1 phosphorylation due
to the oncogenic activation of PI3K- and MEK-dependent kinases,
mimicking protein loss [4]. Indeed, in the cytoplasm p27KIP1 is
unable to exert its inhibitory activity on CDK even in the presence
of anti-mitogenic stimuli.
On the same lesion loss of heterozygosity (LOH) analysis was
then performed. No loss of the wild type allele was observed
(Figure 2). Moreover, the biallelic expression of an uORF-
containing transcript has been observed (Figure 3c), further
confirming that p27KIP1 may act as a haploinsufficient tumor
suppressor [24].
Figure 1. Comparison of the CDKN1B gene among species. (A) Schematic representation of the CDKN1B gene in different species. The uORF
has been reported as grey box while CDKN1B as a yellow one. Similarities at nucleotide level with human sequences have been reported within
boxes. Intercistronic length is also shown. * In chicken CDKN1B 59UTR a second uORF has been described. (B) uORF amino acid sequences in seven
species. In all but one, conservation of the uORF encoded peptide is even higher than p27KIP1. The considered nucleotide and protein sequences are
the following: Human, NM_004064.3, NP_04055.1; Mouse, NM_009875.4, NP_034005.2; Dog, HE804769, CCH35981; Opossum, HE804772, CCH35984;
Chicken, NM_204256, NP_989587; Sloth, HE804770, CCH35982; Megabat, HE804771, CCH35983. Nucleotide and protein sequences alignments
among species have been performed by LALIGN and PRALINE, respectively.
doi:10.1371/journal.pgen.1003350.g001
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The c.-456_-453delCCTT affects p27KIP1 translation
reinitiation by altering CDKN1B uORF length and the
intercistronic distance in a cell cycle–independent
manner
To identify possible additional uORF mutations, we extended
the CDKN1B 59UTR analysis to additional 41 patients with typical
MEN1-like features previously reported negative for mutations in
the CDKN1B coding sequence [17,25]. A c.-469C.T substitution
resulting in a silent change in the uORF was detected in a single
patient but not in healthy controls (see above).
To determine whether the two identified substitutions nega-
tively affect CDKN1B translation, the wild type and mutated
59UTRs were cloned upstream of the firefly luciferase gene
(Figure 5a). By transfecting lovastatin G1-synchronized or
asynchronous HeLa and GH3 cells, we demonstrated that the
c.-456_-453delCCTT, but not the c.-469C.T variant, signifi-
cantly reduced luciferase activity in a cell cycle phase-independent
manner (Figure 6a, 6b). When we analyzed the luciferase mRNA
from the transfected cells by quantitative real-time RT-PCR, we
demonstrated that the effects of the 4-bp deletion are largely due
to reduction in translation rate rather than to changed steady-state
mRNA levels (Figure 6c), in agreement with our observation on
blood CDKN1B mRNA (Figure 3a) and with the trend observed in
large-scale datasets [26].
We then evaluated the effect of the 4 bp deletion on p27KIP1
translation by transfecting HEK293 cells with vectors with either
the wild type or the mutated 59UTRs cloned upstream the
CDKN1B gene (Figure 5b). We confirmed a significant reduction in
p27KIP1 protein levels as a consequence of the 59UTR c.-456_-
453delCCTT mutation (Figure 6d).
In a previous study on HeLa cells using an identical wild type
construct, the CDKN1B 59UTR induced luciferase expression only
during G1 progression or in lovastatin-arrested cells [11].
Although we cannot exclude the presence of DNA variations on
regulatory elements between the two cloned sequences, a possible
biological variability between batches of cells from the same cell
line seems the more plausible explanation. However, similar cell-
cycle independent luciferase activation was observed under our
experimental conditions in three additional cell lines, namely GH3
(Figure 6a), SH-SY5Y and HEK293 (Figure S1). Based on such
observation we may therefore suggest the need for further studies
for better clarifying the cell-cycle dependent translation of p27KIP1
regulated by the CDKN1B 59UTR.
Site-directed mutagenesis (c.-428A.T) was then used to
reintroduce a stop codon in the c.-456_-453delCCTT containing
vector, thus restoring both uORF length and intercistronic
distance (Figure 5c). After transfection, the uORF regulatory
properties were almost completely rescued in the double mutant
compared to the c.-428A.T construct (Figure 7a), further
supporting the hypothesis that the 4 bp deletion affects translation
reinitiation of the downstream CDKN1B ORF. In addition, the
lack of complete recovery of the uORF modulatory activity,
possibly due to differences in the C-terminus of the uORF-
encoded peptide (Figure 7b), further confirms that the CDKN1B
uORF belongs to the class of sequence-dependent uORFs that
Figure 2. The c.-456_-453delCCTT affects protein translation
by reducing reinitiation. Schematic representation of the CDKN1B
59UTR in the wild type (A) and in the c.-456_-453delCCTT carrier (B). The
uORF coding sequence is shown as grey box. Electropherograms for
germline (G) and tumor (T) DNA are shown.
doi:10.1371/journal.pgen.1003350.g002
Figure 3. The c.-456_-453delCCTT does not alter the steady-state levels of CDKN1B allelic mRNA nor the promoter usage pattern. (A)
The wild type and mutated alleles were present at similar level in blood-derived RNA. The amount of both alleles are expressed as differences
between Cq values obtained for mRNA minus Cq for genomic DNA for removing the intrinsic variation between the two qPCR assays. (B) A single
CDKN1B promoter is used in lymphocytes from both deletion carrier (P) and a normal control (NC). M, molecular marker; -, negative control. (C) Both
wild type and mutated alleles are transcribed in pancreatic lesion.
doi:10.1371/journal.pgen.1003350.g003
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exert their inhibitory role by acting in cis to regulate components
of the translation apparatus [19].
The CDKN1B uORF is efficiently translated
To evaluate the ability of the uORF to be translated, which
represents the central point of our hypothesis on the possible
deleterious effects of the c.-456_-453delCCTT change, the wild
type or the mutated 59UTRs were placed upstream of the
CDKN1B open reading frame and the c.-74insC mutation was
introduced by site-directed mutagenesis. This additional DNA
variant leads to the in-frame fusion of the mutated uORF with the
main gene (Figure 5d). As expected, the chimeric product was
detected only in the c.-74insC+c.-456_-453delCCTT transfected
HEK293 cells, and was again associated with a significant
reduction of p27KIP1 expression (Figure 6e). To our knowledge,
this is the first direct evidence of the translation of the CDKN1B
uORF in a cellular system. However, it remains to be clarified if
this peptide has additional biological functions other than
repressing translation of the CDKN1B ORF as an effect of
impaired reinitiation, as suggested for a subset of uORFs [27].
The c.-456_-453delCCTT transcript is less efficiently
loaded onto polysomes than the wild-type one
To elucidate the molecular mechanism by which c.-456_-
453delCCTT determines a decrease in p27KIP1 translational
efficiency, we estimated the relative proportion of the two allelic
mRNAs engaged in translation in the immortalized lymphoblas-
toid cells of the heterozygote patient. To this aim, the cell lysates
were subjected to polysome fractionation through sucrose gradient
ultracentrifugation [28] and we determined the level of each of the
two allelic mRNAs for each fraction. Figure 8a reports the
distribution of ribosomal RNA in the different fractions, showing a
typical distribution with polysomes reproducibly spanning frac-
tions 7–11. The distributions of the wild type and c.-456_-
453delCCTT transcripts present an almost superimposable
pattern, being for both about 90% of the total detectable mRNA
localized in polysomes with a peak corresponding to fraction 9
(compare Figure 8b with Figure 8a). However, when the amounts
of both alleles were expressed as differences between Cq values for
mRNA and for genomic DNA for removing the intrinsic variation
between the two qPCR assays, a clear preponderance on
polysomes of the wild type CDKN1B mRNA could be observed
(Figure 8c), which we can estimate to be of the order of about three
times. Since the levels of the two allelic mRNAs in the cells are the
same (Figure 3a), this implies that the c.-456_-453delCCTT
mRNA suffers decreased average polysomal loading with respect
to the wild type mRNA. Therefore, the two different CDKN1B
mRNAs are differentially loaded in polysomes despite being
present in the cells in the same relative amounts, and despite the
fact that they share a distribution profile on polysomes of different
molecular weights. The result is compatible with a decreased
efficiency of translation reinitiation of the CDKN1B ORF due to
the c.-456_-453delCCTT mutation.
Figure 4. Expression of p27KIP1 and Ki-67 in pancreatic tumors and control tissue. (A–C) Immunohistochemical staining with anti-p27KIP1
antibody. (D) Staining with anti-Ki67 antibody. (A) staining of a control human tonsil. Cells in the lymphatic nodule show the expected strong nuclear
positivity for p27KIP1, while only few of the highly proliferating germinal center (GC) cells express p27KIP1. (B) Sporadic endocrine pancreatic tumor of
an individual with no known germline mutations. The tumor cells show intermediate levels of nuclear immunoreactivity for p27KIP1. (C) Endocrine
pancreatic tumor of the patient having the c.-456_-453delCCTT mutation. Tumor cells show low expression of p27KIP1 in the nucleus but also
expression in the cytoplasm. Endothelial cells (arrows) show the typical strong nuclear positivity and serve as internal control to check for the
adequacy of the staining. (D) Same tissue as in C stained for the proliferation marker Ki-67. Positive nuclei are indicated with arrowheads. The
proliferation rate was estimated to be ca. 1%. Bar, 20 mM. Original magnification: A–D, 2006.
doi:10.1371/journal.pgen.1003350.g004
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The role of uORF mutations in MEN4 and other human
diseases
The data we presented here further confirm the role of CDKN1B
germline mutations in predisposing to a MEN4 syndrome.
Furthermore, they demonstrate that a reduced translation
initiation rate of p27KIP1 due to the ineffective regulatory activity
of its uORF may be associated with transformation. Based on our
data, mutations in the CDKN1B-regulating uORF seem to be rare.
However, previous studies on CDKN1B germline mutations in
MEN1-like patients did not consider the uORF region [8,9,14,16–
18,25,29], and therefore the prevalence of this type of mutation
remains to be established. Our results emphasize thus the need for
the inclusion of the entire 59UTR region of CDKN1B in molecular
testing for MEN4.
Increasing evidence suggests that uORF-mediated translational
control may represent an important mechanism in the regulation
of gene expression. This is supported by the close relationship of
mutations that introduce or disrupt uORFs and the pathophys-
iology of several human diseases, including cancer [30]. To date,
only three well-known hereditary diseases have been associated
with uORF-affecting mutations: i) thrombocythemia due to
thrombopoietin mutation [31], ii) melanoma due to CDKN2A
mutation [32] and iii) Marie Unna hypotrichosis due to mutations
in the hairless gene [33]. Other diseases, such as breast cancer,
Alzheimer’s diseases, arrhythmogenic right ventricular cardiomy-
opathy have also been suggested to be associated to genes which
have uORF-related control [34–36]. However, the pathogenic
effects of deregulated uORF-mediated translation in these cases
remain to be clarified [37].
Many important genes involved in controlling cell growth (i.e.
receptors, oncogenes, growth factors) harbor uORF in their
59UTR [38]. Some of these genes override the uORF-mediated
translational repression and accumulate their protein product in
cancer cells [39]. Translational derepression elements in the
39UTR may counteract the inhibitory activity of uORFs on
translation [39]; however, mutations inducing loss of uORF
function in oncogenes might lead to a similar increase of
translation rate and consequently to malignant transformation.
Conversely, gain of function mutations in uORFs regulating tumor
suppressor genes may reduce translation of protective proteins
leading to tumor formation [32]. Similarly to a point mutation
introducing a regulative uORF in the leader sequence of the
tumor suppressor gene CDKN2A in hereditary melanoma [32], the
4-bp deletion in CDKN1B gene we describe here led to the reduced
production of CDKN1B-encoded protein p27KIP1, probably due to
a decreased translation reinitiation rate, which then results in
predisposition to tumor development.
Conclusions
In conclusion, the CDKN1B mutation functionally characterized
in this study represents a novel example of an uORF-affecting
mutation. Our functional studies show the negative influence of
this deletion on the translation reinitiation at the CDKN1B starting
site thus providing novel insights into the role of uORFs in the
pathogenesis of human diseases.
In addition to the classical mechanisms of degradation by the
ubiquitin/proteasome pathway and by non-covalent cytoplasmic
sequestration, our findings demonstrate that p27KIP1 activity can
also be modulated by its uORF, and mutations affecting this
sequence may lead to reduced expression of p27KIP1 protein.
Materials and Methods
Patients
The cohort of patients screened for mutations in the entire
CDKN1B gene consisted of 25 consecutive patients with two or
more typical MEN1-related symptoms (hyperparathyroidism,
neuroendocrine tumors, pituitary adenoma). Patients were col-
lected and diagnosed at the Division of Endocrinology (Univer-
sity/Hospital of Padova) and at the Familial Cancer Clinic and
Oncoendocrinology (Veneto Institute of Oncology), Padova, Italy,
following the recognized clinical practice guidelines [40]. All
patients had negative mutational screening for MEN1, PRKAR1A
and AIP genes. A second group of additional 41 patients with
similar phenotype has been analyzed only for the uORF sequence
since the rest of the gene has been analyzed and published
previously without finding any pathogenic mutations [17,25]. The
study was conducted in accordance with the Helsinki declaration.
Figure 5. Constructs used in transfection experiments. (A) Either
the wild type, the c.-456_-453delCCTT or the c.-469C.T containing
59UTRs were cloned upstream the firefly luciferase gene. (B) The wild
type/c.-456_-453delCCTT 59UTR were subcloned upstream the CDKN1B
gene. (C) The introduction of the c.-428A.T substitution in the two
former plasmids reported in panel A restores uORF length and
intercistonic distance. (D) Constructs reported in panel B were mutated
introducing a c.-74insC leading to the translation of a chimeric protein
in the double mutant.
doi:10.1371/journal.pgen.1003350.g005
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Local ethical committees from each referring center approved the
study, and all subjects gave written informed consent.
Mutational analysis for CDKN1B gene and LOH
The whole coding region, intron–exon boundaries, and 59- and
39-UTRs of CDKN1B were amplified and directly sequenced as
reported elsewhere [41]. All primer pairs used were designed by
PRIMER3 (http://primer3.sourceforge.net/) and synthesized by
IDT (Leuven, Belgium). Primers for point mutation analysis of the
entire human CDKN1B gene were P0F, 59-agcagtacccctccagcagt-
39; P0R, 59-aaagcccgtccgagtctg-39; P1F, 59-ccaatggatctcctcctctg-39;
P1R, 59-ggagccaaaagacacagacc-39; P2F, 59-ccatttgatcagcggagact-
39; P2R, 59-gccctctaggggtttgtgat-39; P3F, 59-gagttaacccgggacttg-
gag-39; P3R, 59-atacgccgaaaagcaagcta-39; P4F, 59-tgactatggggc-
caacttct-39; P4R, 59-tttgccagcaaccagtaaga-39; P5F, 59-ccccatcaag-
tatttccaagc-39; P5R, 59-cctcccttccccaaagttta-39; P6F, 59-
tgcctctaaaagcgttggat-39; P6R, 59-tttttgccccaaactacctg-39; P7F, 59-
gccctccccagtctctctta-39; P7R, 59-ggtttttccatacacaggcaat-39; P8F,
59-tctgtccatttatccacaggaa-39; P8R 59-tgccaggtcaaataccttgtt-39.
Previously unreported nucleotide changes were screened in 300
healthy, anonymous, unrelated individuals by Tetra-primer
ARMS-PCR [42] and searched in the dbSNP and 1000 genomes
databases (http://www.ncbi.nlm.nih.gov/projects/SNP/; http://
www.1000genomes.org/). The NHLBI Exome Sequencing Proj-
ect - Exome Variant Server database (http://evs.gs.washington.
edu/EVS) has been queried for the c.-469C.T. Primers for
Tetra-primer ARMS-PCR were: hp27delOUTR, 59-agccgctctc-
caaacctt-39; hp27delOUTF, 59-caatggatctcctcctctgttt-39; hp27de-
lINF, 59-cttcttcgtcagcctcccac-39; hp27-469INR, 59-tggcggtggaagg-
gaggctgacgcaa-39; hp27-469INF, 59-gactcgccgtgtcaatcattttcgtc-39.
Gene dosage alteration was assessed by the quantitative
multiplex PCR of short fluorescent fragments (QMPSFs) and by
long-range PCR (LR-PCR) as previously described [41] using the
following primers: CLIF, 59-tggtcagagagtggcctttctc-39; CLIR, 59-
tgccgagtagaggcatttagtca-39; CLIIF, 59-tgtctgtgacgccgttgtct-39;
CLIIR, 59-aagggttttctagcacacataggaa-39; 1IF, 59-gccgcaaccaatg-
gatctc-39; 1IR, 59-acgagccccctttttttagtg-39; 1IIF, 59-ctctgaggacacg-
catttggt-39; 1IIR, 59-aaatcagaatacgccgaaaagc-39; 2F, 59-
tttcccctgcgcttagattc-39; 2R, 59-ccaccgagctgtttacgtttg-39; 3IF, 59-
ccccatcaagtatttccaagct-39; 3IR, 59-gttattgtgttgttgtttttcagtgctta-39;
3IIF, 59-aacttccatagctattcattgagtcaaa-39; 3IIR, 59- tgagc-
gatgtggctcggct -39.
Sequence based-LOH analysis was performed on the pancreatic
lesion by direct analysis of the CDKN1B mutation.
Cell culture, transfection, and protein extraction
The human cervical carcinoma HeLa, the rodent p27KIP1-
negative GH-secreting pituitary adenoma GH3, the human
embryonic kidney HEK293 and the human neuroblastoma SH-
SY5Y cell lines (American Type Culture Collection, Manassas,
VA), were maintained at 37uC in a 5% CO2 in complete 10%
FCS DMEM.
Figure 6. The c.-456_-453delCCTT affects protein translation by reducing reinitiation. Relative luciferase activity for the wild type and the
mutants (c.-456_-453delCCTT, c.-469C.T) 59UTRs was measured in GH3 (A) and HeLa (B) cells. The effects of the 4 bp deletion on luciferase mRNA in
HeLa and GH3 cells (C) and on p27KIP1 level in HEK293 cells (D) are shown. Panel E shows the presence of the chimeric product in HEK293 cells
transfected with the double mutant construct (c.-456_-459delCCTT+c.-74insC), followed by substantial reduction of p27KIP1 expression, demonstrated
by western blot. P-values were calculated using a two-tailed t-test. *p,0,01; EV, empty vector; wt, wild type; error bars, standard deviation.
doi:10.1371/journal.pgen.1003350.g006
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GH3 (1.56105 cells/well), HeLa (1.06105 cells/well), SH-SY5Y
(1.306105 cells/well) and HEK293 (2.56105 cells/well) cells were
plated 24 hours before transfection into 12-well plates. When
necessary, 24 hours after seeding cells have been arrested in G1
phase by a 36-hour treatment with either 10 mM (GH3) or 20 mM
(HeLa) lovastatin. In all cell lines but HEK293 (see below)
transient transfection was performed by Superfect (Qiagen, Milan,
Italy). 1.5 mg plasmid and a ratio mg DNA/ml Superfect of 1:6
following manufacturer’s protocol were used. The pRL-TK
plasmid (Promega) encoding Renilla luciferase was cotransfected
and used for normalization of transfection efficiency. After
3 hours, the medium was changed to DMEM with 2% FCS and
incubated for further 24 hours. Cells were then harvested in
passive lysis buffer (Promega) and the relative luciferase activity
was measured using the Dual-Luciferase Assay System and a
GloMax 20/20 luminometer (Promega) according to the manu-
facturer’s instructions.
For expression experiments, HEK293 cells were seeded into 12-
well plates, grew to 95% confluence and transfected with
Lipofectamine 2000 (Invitrogen, Milan, Italy) following the
manufacturer’s protocol. Cells were harvested 24 hours post-
transfection, lysed in RIPA Buffer supplemented with proteases
inhibitors (MgCl2 10 mM, Pepstatin 1 mM, PMSF 1 mM,
cOmplete 1X (Roche, Monza, Italy)). Samples were clarified by
centrifugation at 13,000 rpm for 5 min at 4uC.
Western blotting
Concentrations of the HEK293 extracted proteins were
determined using the Bio-Rad DC protein assay kit (Bio-Rad
Italia, Milan, Italy) following the manufacturer’s instructions. For
each sample, 20 mg were resuspended in NuPAGE LDS sample
buffer and NuPAGE sample reducing agent (Invitrogen), boiled
for 10 min at 70uC and resolved by SDS-PAGE on 4–12%
NuPAGE gels (Invitrogen) and Mes buffer (Invitrogen). Separated
proteins were transferred onto nitrocellulose membrane by Trans-
Blot Turbo transfer system (BioRad) that was blocked for 2 hours
with 5% non-fat dry milk (BioRad). The membrane was incubated
overnight at 4uC with anti-p27KIP1 monoclonal antibody (BD
Bioscience Heidelberg, Germany) used at 1:300. Expression was
corrected for differences in protein loading by probing blots for
1 hour at RT with mouse anti-ß-actin antibody (clone AC-15
1:5,000, Sigma-Aldrich, Milan, Italy). Blots were developed using
Pierce ECL Substrate (Part No. 32106, Thermo Scientific,
Rockford, IL USA) and exposed to CL-XPosure Film (Thermo
Scientific).
RNA isolation from HEK293 cells, reverse transcription,
and quantitative real-time PCR (qPCR)
For total RNA extraction, HEK293 cells were resuspended in
TRIzol (Invitrogen) and processed according to the manufactur-
er’s instructions. Plasmid DNA contamination was removed by
DNase, treating total RNA twice with Turbo DNA free kit
(Applied Biosystems, Milan, Italy). One mg of DNase-treated RNA
was reverse-transcribed using M-MuLV Reverse Transcriptase
RNase H- (F-572S, Finnzymes, Espoo, Finland). qPCR was done
with Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen)
in an ABI PRISM 7900HT Sequence Detector (Applied
Biosystems). A final concentration of 300 nM for both forward
and reverse primers was used. Primers for qPCR were qLUCF, 59-
gcctgaagtctctgattaagt-39; qLUCR, 59-acacctgcgtcgaaga-39;
qrBActF, 59-agattactgccctggctcct-39; qrBActR, 59-aacgcagctcag-
taacagtccg -39; qhGAPDHF, 59- ctctctgctcctcctgttcgac-39;
qhGAPDHR, 59- ctctctgctcctcctgttcgac-39.
Threshold levels were set at the exponential phase of qPCR
using Sequence Detection software, version 2.4 (Applied Biosys-
tems). The amount of each target gene relative to the proper
housekeeping gene (HK, rat b-actin or human GAPDH) was
determined using a relative standard curve method and the results
Figure 7. Effect of the c.-428A.T restoring mutation. In both GH3 and HeLa cell lines c.-428A.T almost restores the modulation properties of
the CDKN1B wild type uORF (A). Panel B shows the primary sequence differences in the wild type uORF compared with the -456_-453delCCTT+c.-
428A.T.
doi:10.1371/journal.pgen.1003350.g007
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were expressed as a ratio of target gene/HK. A 38-cycle threshold
was set, beyond which the gene was considered undetectable.
Mutation carrier’s RNA, allele specific analysis, and rapid
amplification of cDNA ends (59RACE)
Total RNA from whole blood samples was obtained using
Paxgene Blood RNA Kit (Qiagen) following manufacturer
protocol, while RNA from paraffin-embedded pancreatic tumor
tissue was extracted using a modified RNAzol method, as
previously described [43]. RNA was reverse-transcribed as
described above. Allele-specific analysis was evaluated by qPCR
as described above using two different SYBR assays. A final
concentration of 300 nM for both forward primers and 50 mM for
the unique reverse primer was used (-456_-453del_wtF 59-
cttcttcgtcagcctccctt-39; -456_-453del_mutF 59- cttcttcgtcagcctcc-
cac-39; -456_-453del-R 59-agccgctctccaaacctt-39). Given the dif-
ferent efficiency that may characterize the two different assays, the
value of each allele was referred to the genomic DNA expressed as
DCq (Cq value obtained for mRNA minus Cq value for genomic
DNA). The lack of a possible deletion/duplication of the
corresponding genomic locus was proven by QMPSFs as
described above.
59RACE was performed using 59RACE System 2.0 kit
(Invitrogen) on whole blood derived total RNA following
manufacturer’s instructions. Briefly, first strand cDNA was
synthesized from 2 mg of mRNA by SuperScriptII RNA polymer-
ase reaction using the specific primers GSP1R (59-
gttaactcttcgtggtcc -39). After adding an oligo-dC tail to the cDNAs
39-ends, a PCR reaction has been performed with GSP2R primer
(59-ttctcccgggtctgcacg-39), coupled with an Abridged Anchor
Primer (AAP). The resulting DNA fragments were eluted from
agarose gel and analyzed by direct sequencing, as reported above.
Immunohistochemistry
Immunohistochemistry was performed on an automated
immunostainer (Ventana Medical Systems, Frankfurt am Main,
Germany), according to the manufacturer’s protocols with minor
modifications [44] using the monoclonal anti-p27KIP1 antibody
cited above (1:1,000). The monoclonal MIB5 antibody (1:500,
Dako, Hamburg, Germany) was used to detect the proliferation
antigen Ki-67. Positive controls were used to confirm the
adequacy of the staining.
Cloning and mutagenesis
PCR fragments were obtained by amplification of the mutation
carrier with forward and reverse primers containing extra HindIII
and NcoI sites, respectively (clonF, 59- catcataagcttccacct-
taaggccgcgct -39; clonR, 59- catcatccatggttctcccgggtctgcacg -39).
The PCR product was digested and inserted upstream the
luciferase reporter gene into the pGL3 Control Vector (Promega).
For expression studies the wild type and mutated 59UTRs were
subcloned into pcDNA3.1/p27HA (kind gift of Prof. Sylvain
Meloche, Institute for Research in Immunology and Cancer,
Universite´ de Montre´al, Canada). The c.-469C.T, c.-428A.T
and c.-74insC modifications were introduced by QuikChange II
Figure 8. Polysome profiling of lymphoblastoid cells from the -
456_-453delCCTT mutation carrier. (A) Representative absorbance
profile for RNA separated by velocity sedimentation through a 15–50%
sucrose gradient. The positions of the 40S, 60S, 80S, and polysomal
peaks are indicated. (B) The levels of CDKN1B mRNA (wt and c.-456_
-453del) in each gradient fraction were measured by quantitative real-
time PCR and plotted as a percentage of the total CDKN1B mRNA levels
(wt or c.-456_-453del, respectively) in that sample. Data represent three
independent experiments, with mean 6 SD reported. (C) The levels of
both alleles in each fraction were expressed as relative quantities
calculated from differences in Cq values between mRNA and genomic
DNA for removing the intrinsic variation between the two qPCR assays.
Data represent the mean of three independent experiments 6 SD.
doi:10.1371/journal.pgen.1003350.g008
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XL kit (Stratagene, La Jolla, CA USA) following manufacturer’s
protocol.
Lymphoblastoid cell lines and polysomal RNA extraction
EBV-transformed lymphoblastoid cells were generated by
infection of peripheral blood mononuclear cells from the c.-
456_-453delCCTT mutation carrier with culture supernatant
from the EBV-producing marmoset cell line B95.8 (American
Type Culture Collection) and maintained in RPMI 1640 medium
(Euroclone, Milano, Italy) supplemented with 10% FBS, 1 mM
Na Pyruvate, 10 mM Hepes Buffer, 2 mM Ultraglutamine (Lonza
BioWhittaker, Basel, Switzerland), 1% Antibiotic/antimycotic
(Gibco, Invitrogen Corporation). Cyclosporin A (CsA, Sandoz
Pharmaceuticals AG; Cham, Switzerland) was initially added to
the cultures to inhibit T cell growth (final concentration, 0.7 mg/
ml).
For polysomal RNA extraction lymphoblastoid cells (256106)
were incubated with 100 mg/ml cycloheximide for 4 minutes,
washed once with phosphate buffer saline (PBS), resuspended in
lysis buffer [10 mM NaCl, 10 mM MgCl2, 10 mM Tris–HCl,
pH 7.5, 1% Triton X-100, 1% sodium deoxycholate, 100 mg/ml
cycloheximide, 0.2 U/ml RNase inhibitor, 1 mM DTT] and
transferred to a microcentrifuge tube. After 5 minutes incubation
on ice, the extracts were centrifuged for 10 min at 12,000 g at
4uC. The supernatant was collected and stored at 280uC. The
cytoplasmic lysates were fractionated by ultracentrifugation
(Sorvall rotor, 100 min at 180,000 g) trough 15–50% linear
sucrose gradient containing 30 mM Tris–HCl, pH 7.5, 100 mM
NaCl, 10 mM MgCl2. Eleven fractions were collected monitoring
the absorbance at 254 nm. The RNA in each fraction was isolated
after proteinase K treatment, phenol–chloroform extraction and
isopropanol precipitation. RNA was resuspended in 30 ml of
water. For each fraction 1 mg RNA was reverse-transcribed and
analyzed by qPCR using allele-specific assays as reported above.
Supporting Information
Figure S1 Effect of the CDKN1B 59UTR in HEK293 and SH-
SY5Y cell lines. The wild type 59UTR of the CDKN1B gene, but
not the c.-456_-453delCCTT containing one, is able to induce
luciferase activity in asynchronous SH-SY5Y (A) and HEK293 (B)
cell lines. On the right side of each panel the flow cytometry
evaluation of the corresponding cell line is shown. Data represent
three independent experiments. P-values were calculated using a
two-tailed t-test. *p,0,01; EV, empty vector; wt, wild type; error
bars, standard deviation.
(PDF)
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